• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
RNA (miRNA, RNAi & siRNA) Therapy in Oncology Drug Pipeline Update 2015 Product Image

RNA (miRNA, RNAi & siRNA) Therapy in Oncology Drug Pipeline Update 2015

  • ID: 1196689
  • January 2015
  • Region: Global
  • Bioseeker

Potentially any disease-causing gene, cell type or tissue can be targeted with miRNA, RNAi or siRNA, including those not ’druggable’ with small molecules or protein-based therapies.

There are today 63 companies plus partners developing 96 RNA (miRNA, RNAi & siRNA) drugs in 152 developmental projects in cancer. In addition, there is 1 suspended drug and the accumulated number of ceased drugs over the last years amount to another 28 drugs. Rna (Mirna, Rnai & Sirna) Therapy In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 78 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 54 out of the 54 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 28 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and READ MORE >

Note: Product cover images may vary from those shown



Delivery Format: Desktop App plus Online Access to Updates (One Year)

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Photocure ASA Roche Diagnostics Ltd. Abbott Laboratories Ltd. Pfizer, Inc. Novartis AG Becton, Dickinson and Company (BD)